SuperworthNeuronetics STIM
- Market cap
- $160.8M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 1.0×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $155.1M
- +40% on a year ago
- Net margin
- −19.6%
- Free cash flow yield
- −7.0%
Neuronetics trades at 1.0× sales. Its trailing earnings are negative, so it has no PE. Revenue was $155.1M over the last twelve months, up 40% on a year earlier with a −20% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $17.9M+8% | $20.3M+12% | $17.4M+12% | $16.4M−7% | $18.5M+4% | $22.5M+11% | $32M+84% | $38.1M+132% | $37.3M+101% | $41.8M+86% | $34.5M+8% | $41.6M+9% | |
| Cost of revenue | $6.1M+71% | $4.5M+4% | $4.3M+5% | $4.3M−12% | $4.5M−26% | $7.6M+67% | $16.2M+275% | $20.4M+377% | $20.2M+346% | $20.1M+164% | $18.3M+13% | $20.3M+0% |
| Gross profit | $11.8M−9% | $15.8M+14% | $13.1M+15% | $12.2M−5% | $14M+19% | $14.9M−6% | $15.7M+20% | $17.8M+46% | $17.1M+22% | $21.7M+46% | $16.2M+3% | $21.2M+20% |
| R&D | $2.2M−8% | $2.2M−30% | $2.3M−16% | $2.2M−6% | $2.4M+12% | $5.8M+162% | $1.6M−31% | $1.8M−20% | $1.5M−38% | $1.7M−71% | $1.4M−16% | $1.3M−26% |
| SG&A | $18.5M+3% | $18M−2% | $17.6M−5% | $18.5M+4% | $19.3M+5% | $20.6M+15% | $25.1M+43% | $24M+30% | $22.9M+19% | $25.1M+22% | $23.8M−5% | $21.4M−11% |
| −$8.9M+19% | −$4.4M−43% | −$6.9M−31% | −$8.5M+16% | −$7.7M−13% | −$11.5M+159% | −$11M+61% | −$8.1M−5% | −$7.3M−5% | −$5M−56% | −$9M−18% | −$1.5M−81% | |
| Interest expense | $1.2M+12% | $1.8M+52% | $1.8M+46% | $2M+73% | $1.7M+46% | $1.8M−5% | $1.9M+5% | $2M−1% | $2.2M+28% | $2.3M+32% | $2.3M+18% | $2.1M+8% |
| Net income | −$9.4M+23% | −$5.4M−35% | −$7.9M−25% | −$9.8M+101% | −$13.3M+42% | −$12.7M+136% | −$12.7M+61% | −$10.1M+3% | −$9M−32% | −$7.2M−44% | −$10.8M−15% | −$3.4M−66% |
| −$0.33+18% | −$0.18−40% | −$0.27−29% | −$0.33+94% | −$0.44+33% | −$0.34+89% | −$0.21−22% | −$0.15−55% | −$0.13−71% | −$0.10−71% | −$0.16−24% | −$0.05−67% | |
| 28.9M+7% | 29.1M+7% | 29.5M+5% | 30.1M+5% | 30.3M+5% | 37.1M+28% | 61.5M+109% | 66.2M+120% | 67.3M+122% | 68.8M+85% | 69.6M+13% | 73.1M+11% |
Revenue: Q1 FY17 and Q1 FY18: 6 months less the 3 months printed beside them.
Cost of revenue: Q1 FY17 and Q1 FY18: 6 months less the 3 months printed beside them.
Gross profit: Q1 FY17 and Q1 FY18: 6 months less the 3 months printed beside them.
R&D: Q1 FY17 and Q1 FY18: 6 months less the 3 months printed beside them.
SG&A: Q1 FY17 and Q1 FY18: 6 months less the 3 months printed beside them.
Operating income: Q1 FY17 and Q1 FY18: 6 months less the 3 months printed beside them.
Interest expense: Q1 FY17 and Q1 FY18: 6 months less the 3 months printed beside them.
Net income: Q1 FY17 and Q1 FY18: 6 months less the 3 months printed beside them.
EPS, diluted: 5 periods, Q4 FY21 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 5 periods, Q4 FY21 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Instruments & Supplies nearest Neuronetics' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| STIMNeuronetics | $160.8M | n/m | n/a | 1.0× | +40% | −19.6% | |
| PDEXPro DEX | $199.3M | 15.1× | 16.6× | 2.6× | +16% | 17.6% | |
| UTMDUtah Medical Products | $236.3M | 22.6× | 20.9× | 6.5× | −7% | 29.0% | |
| KEQUKewaunee Scientific | $94.9M | 11.9× | 13.7× | 0.3× | +5% | 3.0% | |
| INFUInfuSystem | $277.6M | 34.0× | 43.5× | 1.9× | +2% | 6.0% | |
| EMBCEmbecta | $380.2M | 4.6× | 11.7× | 0.4× | −8% | 8.6% | |
| APTAlpha Pro Tech | $56.7M | 13.6× | 14.8× | 0.9× | +6% | 6.8% | |
| TCMDTactile Systems Technology | $535.5M | 21.9× | 62.9× | 1.5× | +17% | 7.1% | |
| MDXGMimedx | $569.9M | 97.8× | 21.1× | 1.6× | −2% | 1.8% | |
| NEPHNephros | $38.3M | 22.1× | 28.4× | 1.9× | +24% | 8.4% | |
| MOVMovado | $701.9M | 17.5× | 13.3× | 1.0× | +5% | 6.0% | |
| Peer median | $257M | 19.7× | 18.7× | 1.6× | +5% | 6.9% |
More on Neuronetics
Each number over time
- PE ratio
- Price to sales ratio
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
Its groups
About
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .